Get the Stockscreener App
7.84
4.53%
0.34
After Hours:
7.84
Myriad Genetics Inc stock is traded at $7.84, with a volume of 890.67K.
It is up +4.53% in the last 24 hours and up +8.29% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$7.50
Open:
$7.59
24h Volume:
890.67K
Relative Volume:
0.54
Market Cap:
$729.47M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-6.0308
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
-1.88%
1M Performance:
+8.29%
6M Performance:
-2.00%
1Y Performance:
-67.44%
1-Day Range:
$7.57
$7.945
1-Week Range:
$7.34
$8.10
52-Week Range:
$3.76
$25.25
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
7.84 | 697.83M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
524.58 | 198.17B | 43.21B | 6.58B | 6.17B | 17.28 |
|
DHR
Danaher Corp
|
205.14 | 144.97B | 24.01B | 3.41B | 4.86B | 4.7082 |
|
IDXX
Idexx Laboratories Inc
|
633.32 | 49.29B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
138.23 | 38.73B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
203.77 | 33.69B | 15.70B | 1.24B | 2.01B | 6.9036 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Tools to monitor Myriad Genetics Inc. recovery probabilityJuly 2025 PreEarnings & AI Enhanced Trading Alerts - newser.com
Applying Elliott Wave Theory to Myriad Genetics Inc.Weekly Profit Summary & Real-Time Buy Signal Notifications - newser.com
Lobbying Update: $40,000 of MYRIAD GENETICS INC. lobbying was just disclosed - Quiver Quantitative
Will Myriad Genetics Inc. stock continue dividend increases2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - newser.com
Is Myriad Genetics Inc. stock bottoming outWeekly Trade Analysis & Safe Entry Point Identification - newser.com
Inspire Investing LLC Increases Holdings in Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage - MSN
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know - TradingView
Myriad Genetics: How knowing genetic risks can help women with their healthcare - KATV
Is Myriad Genetics Inc. (MYD) stock considered safe havenWeekly Profit Recap & Verified Trade Idea Suggestions - newser.com
Using RSI to spot recovery in Myriad Genetics Inc.Market Growth Review & Capital Protection Trading Alerts - newser.com
When is the best time to exit Myriad Genetics Inc.Market Weekly Review & Free High Accuracy Swing Entry Alerts - newser.com
News impact scoring models applied to Myriad Genetics Inc.Oil Prices & Free Risk Controlled Daily Trade Plans - newser.com
Measuring Myriad Genetics Inc.’s beta against major indicesMarket Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV - The Manila Times
Dr. Stitt, Jodi Lavery discuss cancer screening fears, genetic testing benefits survey - KOKH
Myriad Genetics Finalizes CFO Separation Agreement - TipRanks
Myriad Genetics (NASDAQ:MYGN) Shares Pass Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Public Employees Retirement System of Ohio Raises Position in Myriad Genetics, Inc. $MYGN - MarketBeat
Why Myriad Genetics Inc. stock is popular among millennialsEarnings Summary Report & High Accuracy Trade Signal Alerts - newser.com
Will Myriad Genetics Inc. (MYD) stock gain from lower interest ratesTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Will Myriad Genetics Inc. price bounce be sustainableJuly 2025 Review & Real-Time Market Sentiment Alerts - newser.com
Will Myriad Genetics Inc. (MYD) stock deliver stable dividendsCEO Change & Long-Term Capital Growth Strategies - newser.com
Is Myriad Genetics Inc. stock attractive for passive investorsJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
Heatmap analysis for Myriad Genetics Inc. and competitorsJuly 2025 Spike Watch & Low Risk High Win Rate Picks - newser.com
Is Myriad Genetics Inc. (MYD) stock ideal for retirement investorsPortfolio Performance Report & Long-Term Growth Portfolio Plans - newser.com
Should Dividend Investors Consider Tecil Chemicals and Hydro Power Ltd in 2025Automated Trading Signals & Create Passive Income With Smart Stocks - earlytimes.in
Myriad Genetics Inc Stock Analysis and ForecastDividend Stock Watch & Free Unlock Stock Analysis - earlytimes.in
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Myriad Genetics announces resignation of principal accounting officer - Investing.com
jscreen, TODAY Show & Mount Sinai Unite for Groundbreaking Cancer Genetic Screening Event in Honor of Breast Cancer Awareness Month - Yahoo Finance
United States Genomics Industryinvestments driving $115B - openPR.com
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack - The Globe and Mail
Myriad Genetics (NASDAQ:MYGN) Shares Down 5.2%Should You Sell? - MarketBeat
Is Myriad Genetics Inc a good long term investmentPortfolio Allocation Tips & Superior Capital Trading - Early Times
Assenagon Asset Management S.A. Buys 240,643 Shares of Myriad Genetics, Inc. $MYGN - MarketBeat
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):